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INTRODUCTION 
  
 2 
INTRODUCTION 
DEFINITION 
 
Abortion is the termination of pregnancy by the removal or expulsion of the 
foetus or embryo from the uterus before the age of viability, resulting in or caused 
by its death (WHO 2009). 
 
An abortion can be spontaneous or induced. A spontaneous abortion is 
beyond the patient’s control and it takes place due to complications of pregnancy. 
An induced abortion can be therapeutic abortion or elective abortion. 
Therapeutic abortion is an abortion induced to preserve the heath of the pregnant 
female while an elective abortion is the abortion done for any other reason.   
 
The term abortion mostly refers to induced abortion of pregnancy, while 
spontaneous abortions are usually termed as miscarriages. 
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MIDTRIMESTER ABORTION 
 
Second trimester, or mid trimester ranges from 12-28 weeks of gestation.It is 
further divided into an early period between 12 and 20 weeks and a late period 
between 20 and 28 weeks. 
 
Mid-trimester abortion constitutes 10-15% of induced abortions. Due to the 
wide spread use of prenatal diagnostic techniques, detection of serious fetal 
anomalies is on the rise. This has led to a drastic increase in the second trimester 
induced abortions.Medical methods of induced abortions in the midtrimester has 
shown considerable development and have proven to be safe and accessible. 
 
The incidence of induced abortion is around 22%. (i.e. more than 46 million 
of 210 million pregnancies in a year result in induced abortions). Second trimester 
pregnancy termination has been reported to be associated with 3-5 times increased 
morbidity and mortality risks when compared to the first trimester termination of 
pregnancy.
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REPRODUCTIVE RIGHTS 
It is the basic right of every couple and individual to decide on the number, 
spacing and timing of their children.They must have adequate information and 
means to exercise their right.It is their right to attain the highest standard of sexual 
and reproductive health. It is also the right of the individual to make decisions 
regarding reproduction without any discrimination, violence and coercion. 
Every woman has a right to her private life. This has been the basis on 
which the government has emphazised and upheld the right of a woman to have 
an abortion. Every woman has the right to access abortion.This is based on her 
right to decide on the number and spacing of her children. The right of women to 
receive information about abortion options is based on the right to freedom of 
expression.  
 
LEGAL ISSUES 
Indian law allows abortion; if the continuation of pregnancy would endanger 
the life of the pregnant women or cause serious injury to her physical or mental 
health.The Indian Medical Termination Of Pregnancy Act has made termination 
of pregnancy legal.It has certain conditions to safeguard the mental and physical 
health of the mother.  
The supremem court has emphasised that right of a woman to her private life 
is implicit according to Article 21 of the Constitution.Her right to abortion is 
based on this article. 
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INDIAN MEDICAL TERMINATION OF PREGNANCY ACT, 1971 
 
In India, Shantilal Shah Committee (1964) recommended liberalization of 
abortion law in 1966 to reduce maternal mortality and morbidity associated with 
illegal abortions. On this basis, 1969 MTP bill was introduced in Rajyasabha and 
Loksabha and passed by Indian Parliament in August 1971. The Medical 
Termination of Pregnancy Act (MTP Act) was implemented from April 1972. The 
implemented rules and regulations were again revised in 1975 to eliminate time 
consuming procedures for approval of places and to make services more readily 
available. 
 
A registered medical practitioner (RMP) is protected under law if pregnancy 
is terminated in accordance with Section 3 of the MTP Act which emphasises the 
importance of the legal consent. 
 
INDICATION FOR TERMINATION OF PREGNANCY: 
There are four grounds based on which MTP can be performed. 
1) MEDICAL GROUNDS 
2) EUGENIC GROUNDS 
3) HUMANITARIAN GROUNDS 
4) SOCIAL GROUNDS 
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MEDICAL GROUNDS 
 
Medical grounds when the continuation of pregnancy is likely to: 
1) Endanger the life of the pregnant women or 
2) Cause grevious injury to her physical and/or mental health as in case of 
severe hypertension ,cardiac disease ,diabetes, psychiatric illness 
,genital cancer ,breast cancer,etc. 
 
EUGENIC GROUNDS 
 
Eugenic grounds when there is a substantial risk of the child being born 
with serious physical or mental abnormalities. 
Eg ; hereditary disorders, congenital malformations ,etc.. 
 
HUMANITARIAN GROUNDS 
Humanitarian grounds when the pregnancy is caused by rape or incest. 
 
SOCIAL GROUNDS 
Social grounds when  
1) Pregnancy resulting from failure of contraceptive device or method. 
2) When in actual or reasonably foreseeable future , her environment 
might lead to risk or injury to her health. 
Abortions on demand are not permitted by the MTP act. It is the medical 
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practitioners responsibility to opine regarding the presence of valid legal 
indication. These indications are also mandatory even in medical methods. 
 
 VALID LEGAL CONSENT: 
 
1. Written consent of the guardian is mandatory in case of termination of 
pregnancy in minors (under 18 years) and lunatics (according to section 3 
of  Indian lunacy act 1912 )  
2.  In adult women over 18 years, termination of pregnancy is permissible 
with her valid written consent. 
 
Rule 8 of MTP Rules recommends that the consent be informed and recorded 
in FORM C. The consent must be recorded every time an early abortion is carried 
out by medical method. In an adult woman, no other person’s consent is required 
except her own. 
 
THE PLACE WHERE MTP CAN BE PERFORMED 
 
The act stipulates that no MTP can be performed at any place other than : 
1. At hospital established or maintained by Government. 
2. A place recognized and approved by the government , under this act. 
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QUALIFICATION OF THE PERSON WHO CAN PERFORM MTP 
1. Postgraduate degree or diploma in Obstetrics and Gynecology 
2. Registered before commencement of the Act with minimum 3 years 
experience in Obstetrics and Gynaecology 
3. Registered after commencement of the Act if: 
- Assisted in minimum 25 MTPs in a government hospital or a training 
institute recognised by the government.  
- Six months of house surgeon ship in Gynaecology and Obstetrics 
- Experience in any hospital of over 1 year in the field of Gynaecology 
and Obstetrics. 
- For pregnancies which have exceeded 12 weeks but is within 20 weeks 
of gestation, opinion of two registered medical practitioners is 
necessary 
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METHODS OF ABORTION ACCORDING TO GESTATIONAL 
PERIOD 
 
LENGTH OF 
AMENORRHOEA 
TECHNIQUE 
TILL 9 WEEKS  Anti-progestins or prostaglandins 
 Vacuum aspiration 
9 – 14 WEEKS Vacuum aspiration (with Cervical                                                                                                                                         
priming after 12 weeks and in 
nulliparous women) 
MORE THAN 14 WEEKS  Antiprogestins + prostaglandins 
 Prostaglandins alone 
 D & E (with cervical preparation) 
 NOT USED 
o Hypertonic saline ,Urea 
o Ethacridine lactate 
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METHODS OF SECOND TRIMESTER ABORTION 
OUTDATED TECHNIQUES 
 The commonly used methods of early 1970s which are outdated now 
are : 
Intra-Amniotic instillation of drugs: 
 20% Hypertonic saline 
 Hypertonic glucose 
 Urea 
 Prostaglandins 
Extra-Amniotic instillation of drugs: 
 0.1% Ethacridine Lactate (Rivanol) 
 Hypertonic saline 
 Prostaglandins 
 Mifepristone and Misoprostol 
Extra Uterine methods: 
 I.M. PGF2α 
 I.V./I.V oxytocin 
Extra-Amniotic insertion of devices: 
 Sterile catheters 
Surgical methods: 
 Dilatation and Evacuation 
 Aspirotomy and Hysterotomy. 
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Drawbacks of these methods: 
- The intra amniotic space had to be punctured in many methods. 
- Foley catheter was introduced into the extra amniotic space 
- The induction to abortion interval was relatively long 
- There was a need for curettage after the expulsion of fetus 
- Hypertonic saline had the risk of causing disseminated intravascular 
coagulation.  
 
Medical abortion methods have low morbidity. Recently is has become better 
accessible. 
 
MEDICAL TERMINATION OF PREGNANCY 
Medical abortion, being simple safe and effective and without risk of 
invasive procedures and anaesthesia is becoming method of choice in many 
centres and has successfully replaced surgical termination of pregnancy; the 
success rate is also high as 95 %. 
 
The management of second trimester abortion changed with the advent of 
prostaglandin analogues. The subsequent introduction of Anti-progestin, 
Mifepristone, shortened the induction abortion interval and reduced the dosage of 
Misoprostol required, though the cost of Mifepristone and Misoprostol 
combination is still high and is not affordable by many in a resource poor setting.
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The following strategies can be adopted to make medical abortions safer and 
easily feasible in India. 
1. Continue Clinical / Acceptability studies:  
It enables the provider know if the woman likes the method and also helps the 
provider to gain experience. 
2. Conduct Non-Clinical studies: 
It is a research done to record the experience of the women and to assess 
knowledge of the provider. 
3. Increase provider knowledge: 
 New training centres for medical abortion should be established  
- Training for medical abrortion should be incoporated into the 
already existing MTP courses. 
- The national guidelines should be made flexible to facilitate 
adoption on evidence based regimen. 
4. Increase client knowledge: 
The client knowledge can be improved by  media outlets, 
magazines, talk shows, school health talks. 
5. Document serious adverse effects: 
The registered MTP provider must report any serious adverse event 
during the monthly MTP reporting. 
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METHODS OF MEDICAL TERMINATION OF PREGNANCY 
PRINCIPLE 
 
Cervical ripening done prior to surgical termination of pregnancy reduces 
the cervical injury and other operative morbidity. Prostaglandin analogues induce 
cervical ripening in two ways. By acting directly on the cervix and by stimulating 
myometrial activity concomitantly.The prostaglandin receptors are present 
throughout the pregnancy so they play a significant role in the regulation of 
uterine contractility and their analogues are effective for termination of 
pregnancy. Naturally occurring prostaglandins are potent stimulants of uterine 
contractility and they cause ripening and dilatation of the cervix. 
 
DRUGS USED 
 
CARBOPROST  
 
Carboprost (15 (S)-15-methyl PGF 2α) was one of the first prostaglandin 
analogue to be tested clinically for second trimester abortion. It can be used intra 
amniotically or given I.M. It is associated with high incidence of gastro intestinal 
side effects. So it is not used as the method of choice for medical abortion. It can 
be used if other methods fail. 
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SULPROSTONE 
 
 Sulprostone (16 phenoxy-ω-17, 18, 19, 10-tetranor PGE2 methyl 
sulphonylamide) was used in the 1980s for the second trimester abortions. It 
caused myocardial infarction and other cardiovascular complications due to 
coronary vasospasm which led to its withdrawal from the market. 
 
GEMEPROST 
 
Gemeprost is a PGE1 analogue and is used as a vaginal pessary. It has been 
used for ripening and dilating the cervix before vacuum aspiration in late first 
trimester and early second trimester termination of pregnancy. It is a well 
established method of second trimester abortion and is more effective when 
compared to intra-amniotic carboprost or extra-amniotic or intra cervically 
administered PGE2. 
 
MISOPROSTOL 
 
Misoprostol is a synthetic PGE1 analogue (15-deoxy-16-hydroxy-16 -
methyl PGE1), which was initially developed for the prevention and treatment of 
peptic ulcer. Misoprostol is manufactured as 100 and 200 microgram and can be 
used as orally, rectally and vaginally. 
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PHARMACOLOGY: 
Following oral administration of this drug ,it gets absorbed quickly and de-
esterised to its active pharmacological form misoprostol acid. Concentration of 
this metabolite reaches its peak in plasma by 30 minutes and declines rapidly with 
a half life of 20 minutes. Primary site of metabolism of this drug is in liver and 
less than 1 percent of this metabolite is excreted in urine. Dose of the drug needs 
adjustment when used in patients with liver disease whereas it is not required in 
patient with renal disease and not on dialysis. Misoprostol does not affect hepatic 
mixed function oxidase (Cytochrome P-450) enzyme system. 
 
Vaginal administration has the advantage of reducing gastrointestinal side 
effects and exerts profound effect on reproductive tract. After application in the 
posterior fornix, plasma concentration reaches peak by one to two hour and then 
slowly declines. 
 
After oral and vaginal administration of this drug, intrauterine pressure 
begins to increase by 8 and 25 minutes and reaches maximum by 25 and 46 
minutes respectively. When compared with oral administration,vaginal 
misoprostol caused significantly higher level of maximum uterine contractility. 
Cumulative dose up to 2200 mg has been found to be tolerated by expectant 
mothers with no serious side effects when administered over 12 hours. 
Misoprostol has long lasting action following vaginal administration than 
sublingual and oral route. 
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SIDE EFFECTS  
 
Side effects of misoprostol are dose dependant.They are  
- nausea 
- vomitting 
- diarrhoea 
- abdominal pain 
- chills  
- shivering and fever . Myocardial infarction and bronchospasm has 
not been reported yet with the drug. 
 
TERATOGENICITY 
Ingestion of misoprostol in the first trimester in an unsuccessful effort to 
induce abortion causes congenital facial paralysis (moebius syndrome) and 
limb defects in the infants. 
 In a recent case control study, malformations like 
- Transverse limb defects 
- Ring shaped constriction of extremities  
- Arthrogryposis 
- Hydrocephalus 
- Holoproscencephaly 
- Exstrophy of the bladder has been reported in infants. 
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MIFEPRISTONE or RU-486 
   
It is the anti-progestin approved for use in termination of pregnancy. This drug 
helps in two ways: 
1. By causing cervical dilatation and reducing its resistance to dilatation 
2. By increasing the sensitivity of uterus to exogenous prostaglandinds and 
thus shorten the induction abortion interval, increase the successful 
termination of pregnnancy and reduce the total dose of PG required. 
 
NITRATES 
 
Human studies have shown that nitric oxide donors are effective in 
ripening the cervix in first trimester abortions before suction evacuation of the 
uterus, though they are less effective than prostaglandin analogues. However they 
are more acceptable to patients as the side effects of nitric oxide donors are lower 
when compared to prostaglandin analogues. 
 
Nitroglycerine was first synthesised in 1846 by Sobrero who observed that 
a small quantity of oil substance placed on tongue elicited a severe headache. 
Based on this evolved other organic nitrates like amylnitrates, isosorbide dinitrate, 
isosorbide mononitrate, erthrityl tetranitrate. The empirical observation was that 
they could be safely used for the rapid, dramatic relief of symptoms of angina 
pectoris led to their wide spread use by medical professionals. 
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CHEMISTRY  
 
They are polyol esters of nitric acid. Nitrate esters are characterised by C–
O–N O2 (Carbon- Oxygen-Nitrogen) compounds. They are high molecular mass 
nitrate esters and are in solid form. The fully nitrated polyols are lipid soluble 
whereas incompletely nitrated metabolites are more soluble in water. They are 
capable of denitration to release Nitric Oxide (NO). Hence they are called Nitro 
Vasodilators. 
 
 MECHANISM OF ACTION 
 
When Nitric Oxide (NO) is released by denitration into the smooth muscle 
cell it activates the Guanylate Cyclase in vascular smooth muscle cells and 
converts GTP (Guanosine Triphosphate) to cGMP (Cyclic Guanosine 
Monophosphate) and increase intracellular cGMP levels. This cGMP in turn 
blocks the conversion of Myosin light chain kinase to phosphorylated Myosin 
light chain kinase which is helping in contraction of smooth muscles. Also cGMP 
blocks the entry of calcium into the cell thereby causing smooth muscle 
relaxation. 
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PHARMACOKINETICS  
Nitric oxide (NO) is a simple free biologically active radical gas, soluble in 
both water and lipid and therefore freely diffusible in cell environment. Nitric 
oxide is synthesized from the amino acid L–Arginine, has a short half life 
(approximately 4 seconds) and it is not stored in vivo. The synthesis of NO is 
regulated by NO synthases (NOS) of which three isoforms are identified: 
inducible NOS (iNOS), endothelial NOS (eNOS) and neuronal NOS (nNOS).  
 
 Nitric oxide synthases require calcium / calmodulin for activation Nitric 
oxide is rapidly converted to the final metabolites nitrate and nitrite. This reaction 
is catalyzed by transition metals including iron. The half life of NO and the ratio 
of nitrate and nitrite in aqueous solutions, depend upon surrounding conditions 
i.e., presence of oxygen-derived radicals, pO2, pH and concentrations of transition 
metals and thiols. Nitric oxide is a mediator in many biological processes such as 
inflammation, immune response, smooth muscle relaxation, vascular homeostasis 
and neurotransmission. 
 
In the female reproductive tract NO is involved in ovulation, tubal 
transport, implantation, pregnancy maintenance, labor and delivery.Since they are 
lipid soluble, they are well absorbed from buccal mucosa, intestines and skin. On 
oral route they are denitrated by glutathione reductase. Duration of action depends 
on the rate of absorption from the site of administration and the rate of 
metabolism. 
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Isosorbide Mononitrate is an active metabolite of Isosorbide Dinitrate.It 
undergoes little first pass metabolism when administered orally.So Bioavailability 
is high. Inter individual differences are minimal and longer acting (T1/2 4- 6 
hours). The low rate of side effects when administered vaginally reflects the first 
uterine pass effect and its high uterine and low serum concentrations. 
 
ADVERSE EFFECTS: 
 
There are no documented side effects of nitric oxide when administered 
vaginally.Side effects of nitric oxide when given through other routes are: 
 Headache 
 Dizziness 
 Palpitation 
These are mostly due to vasodilatation. 
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COMPLICATIONS ASSOCIATED WITH MTP: 
 Usually only illegal abortions are considered unsafe abortions. But 
complications can occur in any induced abortions. These complications depend 
upon the following conditions. 
 Patient’s pre-abortal health status 
 Gestational age of the foetus 
 Person who provides MTP 
 Facilities available in the MTP centre 
   
MORTALITY 
 Below 8 weeks pregnancy is 0.5% 
 9-12 weeks pregnancy is 1.6% 
 11-12 weeks pregnancy is 3.3% 
 Risk increases by 50 % per week of gestation 
 
Common causes of maternal morbidity and mortality are 
1. Uterine haemorrhage  1-4% 
2. Cervical injury 0.01-1% 
3. Uterine perforation  0.1-0.28% 
4. Injury to bladder and 
intestines 
0.05 – 0.1% 
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OTHER COMPLICATIONS: 
1. Retained products 
2. Continuation of pregnancy 
3. Pelvic cellulitis 
4. Pelvic abcess 
5. Tubo ovarian mass 
6. Pelvic thrombophlebitis 
 
SERIOUS COMPLICATIONS 
1. Anaesthetic reactions 
2. Embolic events 
3. Hemorrhage 
4. Infection 
5. Septicemia 
6. Peritonitis 
7. Endotoxic shock 
8. Tetanus 
9. Acute renal failure 
10. DIVC 
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LATE COMPLICATIONS: 
 
1. Infertility 
2. Ectopic pregnancy 
3. Recurrent abortions 
4. Premature deliveries 
5. Cervical incompetence 
6. Rh isoimmunisation 
7. Asherman’s syndrome 
8. Placenta previa 
9. Adherent placenta 
10. Rupture of uterus during pregnancy and labour 
 
.
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REVIEW OF LITERATURES 
1) METHODS OF ABORTION 
2) MISOPROSTOL 
3) MIFEPRISTONE 
4) NITRATES 
 
METHODS OF ABORTION 
 
The earliest available information regarding mid trimester abortion is with 
the usage of quinine and ergot preparations dating back to 17
th
 century , they 
being abandoned because of almost 100% failure. Although a very good adjuvant 
to other methods of abortion oxytocin itself in high concentration is not effective 
because the uterus is not so sensitive to it as it is so towards term. 
 
From 1946 – 1952 in Japan and United States from 1960 and in India from 
1970 hypertonic saline (20% NaCl) came into vogue as a safe and effective 
method. The induction-abortion interval is between 22 – 39 hrs with the success 
rate of 80 %. However there were complications noted in the form of hemorrhage, 
infection, hypernatremia and inadvertent intravascular injections leading to coma, 
convulsion and death. Hypertonic saline has a 0.8% risk of causing disseminated 
intravascular coagulation. This is because hypertonic saline may get absorbed into 
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the intravascular compartment after an inadvertent intramuscular injection or 
intraperitoneal injection or from the amniotic cavity. This may lead to 
hypernatremia and necrosis of the affected tissues.  
Utus Paste (semi solid soap mixed with potassium iodide and astringents) 
instilled in extra-amniotic space was introduced in 1968 and abandoned in 1974 
due to high failure and infection. In 1971 urea solution in strength of 40 – 60% 
was used intra amniotically with an average induction abortion interval of 44-51 
hrs. Urea alone is not ideal abortifacient needing back up with PGF2 alpha 
analogues. With improved methods being available the use of urea as an 
abortifacient drug has been given up.  
 
Rivanol is a dye with antiseptic properties. It is less toxic than hypertonic 
saline. Rivanol causes chemical trauma to the fetal membranes and decidua, 
which stimulates endogenous PG and thromboxane production resulting in 
cervical ripening and initiating labour. The induction abortion interval ranges 
from 25 to 40 hrs .This could be reduced to 15 -20 hrs when oxytocin was used 
simultaneously. Oxytocin can cause serious side effects like water intoxication 
during I.V infusion. 
 
Later in 1974 intrauterine instillation of glucose and mannitol were 
introduced but abandoned because of high failure rates and high incidence of 
infection. 
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SURGICAL METHODS: 
 
Vacuum aspiration and dilatation and evacuation: 
 
Vacuum aspiration is the surgical method used for first trimester 
termination of pregnancy. This procedure involves emptying of the uterus with a 
suction curette and blunt forceps. This procedure can also be used during the early 
second trimester. The risk of complications increases with advancing gestational 
age. 
 
There is a 15 – 30% increase in the risk of major complications with each 
week of delay beyond 8 weeks of gestation. In between 12 and 15 weeks of 
gestation it is the clinician’s decision regarding the method of abortion based on 
his skill and experience. Abortion above 12 weeks of gestation should be taken up 
by the senior staff member. Suction evacuation can be used for abortions upto 15 
weeks of gestation without need of specialized instruments if the clinician has 
sufficient expertise in it.  
 
The complications can be reduced by prior cervical priming and dilatation. 
Cervical trauma during surgical abortion is found to be less than 1%. The rate is 
lower when abortions are performed by experienced professionals and done early 
in pregnancy. The WHO and RCOG recommends ‘cervical priming to be done 
before surgical method of abortion for pregnancy over 9 weeks for nulliparous 
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women, for women younger than 18 years of age, and for all women with 
pregnancy more than 10 weeks. Mechanical dilatation, Laminaria tents, PG 
analogues or mifepristone can be used to produce cervical dilatation. PG 
analogues are found to be safer for cervical dilatation than mechanical methods 
and laminaria tents. Duration of treatment determines the degree of cervical 
dilatation. Misoprostol and mifepristone combination has been shown to be 
effective for cervical priming before first trimester surgical abortion.  
 
Gottileb et al 1991 conducted a study constituting 127 women at 13-14 
weeks of gestation.There was no case of cervical injury or uterine perforation or 
recurettage during the study. The post abortion infection rate was 1.6%. The 
average amount of blood loss was 49ml (range 0-100ml), and only around 6 
patients had blood loss >100ml. These results were similar when same procedure 
was used in the first trimester ,without any additional complications when PG 
analogues were used for pretreatment. 
 
Dilatation and Evacuation: 
 
Dilatation and evacuation (D&E) is the surgical method of choice at above 
13 weeks of gestation. The suction evacuation is an appropriate method for 
between 12 and 15 weeks of gestation whereas D&E is the safe,convenient and 
effective method for above 15 weeks of gestation RCOG (2004). Safety and 
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efficacy of D&E for mid-trimester pregnancy termination by specialist 
practitioners is confirmed by the evidence available. D&E is found to be faster 
safer and more efficacious when compared to prostaglandins like PGF2alpha. 
Preoperative cervical priming reduces the cervical injury due to D&E in the 
second trimester. 
 
Extra ovular placement of rubber tube was advocated by George (1979) for 
mid trimester abortion with prolonged induction – abortion interval being the 
major problem. Midtrimester abortion was induced with No.12 rubber catheter, 
96% aborted within 40 hours  
 
Saxena S.C and Sharma 1980 have studied termination of pregnancy using 
rubber catheter and Ryle’s tube in 70 cases with 86.9% success rate. 
PROSTAGLANDINS: 
 
The term prostaglandin was coined by Van Euler in 1935 after he isolated 
a substance from the accessory glands of the male genital tract.  Naturally 
occurring PGs like PGE1, PGE2, PGF2α are effective stimulants of uterine 
contractility  and it cause cervical priming and dilatation. The prostaglandin 
receptors are present throughout the pregnancy so they play a significant role in 
the regulation of uterine contractility and their analogues are effective for 
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termination of pregnancy. Naturally occurring prostaglandins undergo a rapid 
metabolism and is associated with high incidence of side effets. So it was replaced 
by prostaglandin analogues which was more suitable for clinical practice. 
 
Gemeprost is a PGE1 analogue and is used as a vaginal pesssary. It has 
been extensively used as a non surgical method to dilate the cervix before VA in 
late first and early second trimester abortion. 
The advent of PGs and PG analogues led to the improvement of medical 
abortion and there was a reduction in the risk for complications and side effects. 
Medical abortion further improved when mifepristone became available in the 
1980s.  
Mifepristone shortened the induction to abortion interval and reduced the 
requirement of dose of PG analogues. Nowadays medical abortion has become the 
method of choice in many countries. 
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SIDE EFFECTS OF PG ANALOGUES: 
 
PGs have a stimulatory effect on the endometrium due to which it causes 
side effects like nausea, vomiting and diarrhea. Gemeprost is more frequently 
associated with diarrhoea whereas misoprostol causes fever. Some of the rare 
compications are  uterine rupture, hemorrhage and cervical tear. Both misoprostol 
and gemeprost may cause uterine rupture rarely whether or not  priming with 
mifepristone was done. In a women without previous scar the incidence of uterine 
rupture is around 0.1% - 0.2% in the second trimester termination of pregnancy 
using mifepristone and gemeprost. Prolonged retention of placenta is usually 
associated with major bleeding. 
Mifepristone and misoprostol has reduced or eliminated the drawbacks of 
medical abortion with older methods like  
- longer duration of labour,  
- long hospital stay 
- need for  an invasive curettage  
MISOPROSTOL 
 
Misoprostol is a PGE2 analogue, produced and used since 1991 by Searle, 
to prevent peptic ulcer disease induced by NSAIDS.Von Euler (1935) found 
prostaglandins as an abortifacient. 
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 Vaginally administered misoprostol has 3 times increased 
systemic biavailability when compared to orally administered misoprostol. In a 
comparative study of oral and vaginal misoprostol in the second trimester 
termination, 90% of vaginal group aborted in 48 hrs and 69% of the oral group 
aborted in 48 hrs. Vaginal pH does not appear to influence the efficacy of 
intravaginal misoprostol. 
  
Misoprostol is over 70% effective in terminating pregnancy within 48 hrs 
when used in second trimester medical management of abortion. Misoprostol is 
uterotonic and provides an effective alternative to other methods of midtrimester 
termination. 
 
A regimen using a combination of mifepristone 200mg and vaginal 
misoprostol   ( 600-800 mcg as first dose ) and oral misoprostol (400mcg every 3 
hrs for 4 doses ) gave the highest complete abortion rate (97% ) and shortest 
induction abortion interval ( 6.5 hrs )  
 
When mifepristone pretreatment was used before vaginal misoprostol, 
,abortion rate was 90% in 24 hrs and induction abortion interval was 9 hrs. 
 
In a randomized controlled trial to compare the effectiveness of 6 and 12 
hrly administration of vaginal misoprostol for second trimester pregnancy 
termination, it was reported that misoprostol (600 mcg ) administered at 12 hr 
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interval was associated with fewer adverse effects and was as effective as 6 hour 
interval and there was no significant difference in the mean induction to abortion 
interval at 6 hours ( 16hrs ) and 12 hrs (16 hrs ). 
 
The efficacy of 400 mcg of tablet misoprostol inserted in the vagina every 
12 hrs for a maximum of 4 doses was compared with extra amniotic ethacridine 
lactate for second trimester MTP. The mean induction to abortion interval was 
shorter in misoprostol group (15.5 hrs) and rate of successful abortion within 48 
hrs was 95 %.  
 
Women who did not abort within 48 hrs (10%) required further 
interventions. They needed PGE2 vaginal suppositories or PGF2α injection or D 
&E or oxytocin infusion. 
 
Routine antibiotic prophylaxis may prevent upto half of all post 
termination of pregnancy infections and is highly cost effective.Second trimester 
abortion is not associated with increased complications when compared to first 
trimester termination of pregnancy in 5 year experience. There was no increase in 
complications when misoprostol was used in a woman with previous cessarian 
section when compared with an unscarred uteri. C.Reinun MD 1999 reported that 
there are good conception rates post abortally with use of misoprostol. 
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MIFEPRISTONE AND MISOPROSTOL COMBINATION 
 
Only a few countries use the medical abortion regimen of mifepristone 
followed by a prostaglandin analogue after 2 days. Research attempts have been 
hampered due to limited access to the drug. Mifepristone-prostaglandin 
combination regimen has developed since approval and the medical method has 
now become more effective and better tolerated than ten years ago. In the present 
day regimen the dose of mifepristone is reduced to 200mg which is one third of its 
original dose without compromising its efficacy. Misoprostol is the most 
commonly used PG analogue in the regimen and this has made medical abortion 
safer and more cost effective. In women beyond 49 days LMP vaginally 
administered misoprostol has a better efficacy when compared to orally 
administered drug though many women prefer oral administration. This 
combination regimen has proven to be more acceptable to women and safe when 
administered under proper conditions. 
 
Mifepristone undergoes rapid absorption after oral administration and has a 
half life of 30 hrs. It binds to the existing small amount of alpha acid glycoprotein 
and thus is quickly saturated. So oral administration of 100-800 mg mifepristone 
has similar peak serum levels.  
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Heikinheimo et al evaluated the dose response of mifepristone.The drug 
followed a non linear pharmacokinetics in both pregnant and non pregnant 
women. When a single dose of more than 100mg is administerd orally it produced 
only a slightly different serum peak concentrations.These pharmacokinetics data 
proved that smaller doses of mifepristone can be administered than the registered 
dose of 600mg with comparable efficacy. 
 
World Health Organisation demonstrated repeated small doses ( 5 doses of 
25 mg given at 12 hour intervals ) or a single dose of 200 mg followed by a 
suitable prostaglandin is equally efficacious as a 600mg single dose. This is 
implemented in China where repeated small doses is used. WHO findings have 
been confirmed by other researchers. 
 
NITRIC OXIDE: 
 
Cervical ripening is defined as an increase in softening, distensibility and 
effacement of cervix occuring physiologically prior to onset of labour.Studies in 
rats have suggested that cervical ripening is associated with an increase in NO 
production. 
 
Nitric oxide (NO ) is an inflammatory mediator formed by the action of 
Nitric oxide Synthase (NOS). It has been associated with a lot of physiological 
and pathological processes in the female reproductive system. Chwalisz et al., 
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(1997) demonstrated the role of Nitric Oxide Donors in inducing Cervical 
ripening in guinea pigs. Thomson et al., (1997) demonstrated that NO donors 
caused cervical ripening in human cervix. 
 
 NO donors produced similar effects on cervical histology as that of 
cervical ripening at term with an inflammatory infiltrate and disruption of 
organisation of collagen fibrils.No effect on cervical dilatation was found in the 
study by Chwalisz et al ., (1997). 
  
But Jane E Norman , Andrew J. Thomson , Ian A Greer (1997 ) have 
found that Iso sorbide Mononitrate (40 mg ) applied in a single vaginal dose 
lowered the cumulative time for abortion compared to control group. 
Hence these studies clearly indicate that NO donors can induce cervical 
ripening in either early or mid pregnancy when applied locally to human cervix 
without much of side effects. Also the use of NO donors is associated with lower 
incidence of abdominal pain and bleeding PV. 
 
In inflammation iNOS can be induced by cytokines (IL-1, IL-2, IL-12), 
TNF-α, interferon gamma (IF-γ) and endotoxins, where NO is synthesized with a 
delay of 6-8 hours after stimulation. Newly synthesized NO, in turn, can stimulate 
the formation of cytokines, such as IL-8 in mast cells in the endometrial stroma 
during implantation. Nitric oxide can regulate COX activity, both constitutive 
COX-1 and inducible COX-2 and thereby affect the production of PGs under 
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normal and inflammatory conditions To take benefits of the biological effects of 
NO clinically, one has to utilize NO donors which, when metabolized, release 
NO. Thus, the nitric oxide donors glyceryl trinitrate (nitroglycerine), sodium 
nitroprusside and isosorbide mononitrate (IMN) are used for treatment of angina 
pectoris, acute myocardial infarction and congestive heart failure.  
 
In the pregnant uterus NO donors have been used as uterine relaxants. 
Nitric oxide donors also promote cervical smooth muscle relaxation in early 
pregnancy as well as at term and have been applied clinically as cervical ripening 
agents. 
 
Isosorbide mononitrate is manufactured for oral administration as a 
vasoactive agent, causing vasodilatation. ISMN is a potent drug, being rapidly 
absorbed and almost 100% bio available, as there is no significant first pass 
metabolism. Peak levels in plasma occur within one hour and the half-life is 5 
hours. Isosorbide mononitrate is excreted via the urine.  
 
In gynecological practice ISMN is preferentially administered per 
vaginum, when peak serum levels are half of the levels after oral administration 
but remain constant at least for six hours. It is suggested that ISMN given per 
vaginum, by a first uterine pass effect leads to higher concentrations in the uterus 
than in the serum thereby maximizing the desired effect.  
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A study conducted in Portugal by Nuneset al., who reported that the 
association of the NO donor GTN (500 mg/kg) with dinoprostone (2 mg) in 99 
women was more effective than dinoprostone alone in 97 women for cervical 
ripening and labour induction at term. A limitation of their study was that they did 
not evaluate the cervical-ripening effect of GTN alone. This beneficial effect of 
combination therapy (an NO donor and a PG analogue) is not unexpected and has 
biologic plausibility because the mechanism of action of NO donors and PGs is 
different and their combined use may be synergistic and lead to more effective 
cervical ripening. 
 
A study conducted by Abdullah MS et al proved that a combination 
regimen of isosorbidemononitrate and misoprostol is more efficacious than 
misoprostol alone in n causing quicker cervical ripening and shortening of 
induction labour interval. 
 
Nicoll AE et al conducted a study to determine the effects of vaginally 
administered isosorbide mononitrate (a nitric oxide donor) on maternal and fetal 
hemodynamics in pregnant women. They proved that vaginal administration of 
20-40mg of ISMN does not produce any clinically significant hemodynamic 
effects on the fetus and mother . 
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 ISMN when given to an outpatient resulted in shorter duration between  
admission and delivery, and required less prostaglandin use and was associated 
with lower incidence of uterine tachysystole . 
 
A study conducted in Finland University of Helsinki showed that NO; a 
free Radical gas with a short half life is a fundamental mediator of cervical 
ripening. As the ideal cervical-ripening agent is one that induces cervical 
remodeling without stimulating uterine activity, NO donors may be such agent as 
they relax the myometrium while inducing cervical ripening.  
 
Eppel et al showed in a randomized controlled study that combination of 
ISMN and gemeprost resulted in a shorter induction abortion interval when 
compared to gemeprost alone. Studies demonstrated that the NO donors, GTN and 
IMN, were effective cervical-ripening agents in pregnancy at term.. 
 
The ideal agent for cervical softening should be clinically effective, it 
should have a low side effect profile and it should be easy to administer. We 
hypothesize that the cervical ripening effects of nitric oxide donors and of 
prostaglandin might be additive.So if a small dose of nitric oxide donor is given in 
combination with a small dose of prostaglandin it will cause effective cervical 
ripening. Such combination might reduce the side effects associated with larger 
doses of either agent used alone. Combination therapy of prostaglandins with 
nitrates might therefore be an ideal method for second trimester termination of 
pregnancy.  
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AIM OF THE STUDY 
 
1. Our aim is to compare the traditional use of vaginal misoprostol versus 
misoprostol and Isosorbide mononitrate in medical management of second 
trimester abortions. 
 
2. The comparison involves aspects of efficacy which are evaluated by means of 
the difference in success rate of inducing abortion, induction to expulsion period, 
rate of manual/ surgical removal of the placenta and the rate of post abortive 
haemorrhage. 
 
3. The comparison also includes the safety profile according to the differences in 
the incidence of side effects in both groups of the study e.g., fever, headache, 
chills, nausea and vomiting. 
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MATERIALS AND METHODS 
 
  The study was conducted in the labour ward of INSTITUTE OF 
OBSTETRICS AND GYNAECOLOGY, EGMORE (IOG) in the period from 
October 2014- July 2015. The patients included in the study were those with 
pregnancies from 12 to 20 weeks of gestational age undergoing induced abortion. 
The assessment of gestational age was based on Last Menstrual Period (LMP) and 
ultrasound measurement. 
 
Following appropriate counselling and after taking informed consent by 
explaining about the procedure, associated complications and need for surgical 
evacuation as and when necessary. Required lab tests were done. Women were 
greater than 16 years old, healthy , 12 weeks to 20 weeks of gestational age 
confirmed by sonogram , and desiring an abortion. 
 
The inclusion criteria were : 
1. Patients requiring termination of pregnancy ( in accordance with MTP Act ) 
from 12 weeks to 20 weeks of gestational age. 
2. Women greater than 16 years of age. 
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3. USG confirmation of 
 Gestational Age 
 Anomalies 
4. Willingness to comply with visit schedule. 
5. Willingness to have a surgical abortion if indicated. 
 
Indications for Termination: 
1. Anomalous baby 
2. Intra uterine foetal demise (IUFD) 
3. Termination for Social and Medical causes 
4. Contraception failure 
5. Severe Oligohydramnios 
6. Severe preeclampsia or imminent eclampsia 
7. PPROM 
 
Exclusion criteria were: 
1. Pregnancy below 12 weeks and above 20 weeks. 
2. Previous uterine scar. 
3. Hemorrhagic Disorders. 
4. Long Term Anticoagulant and Corticosteroid therapy. 
5. Known allergy to Mifepristone and Misoprostol. 
6. Cardiovascular disorders – Angina, valvular heart disease, arrhythmia or 
cardiac failure 
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7. Contraindications to mifepristone including chronic systemic corticosteroid use 
or adrenal disease. 
8. Contraindications to misoprostol , including Glaucoma, Mitral stenosis, sickle 
cell anaemia, poorly controlled seizures. 
 
Methodology:   
 Study population consists of 100 pregnant women within gestational age of 
12- 20 weeks. 
 
Women were divided into two groups: 
Group 1 – Combination of 400 mcg of misoprostol and 40 mg of ISMN placed 
intravaginally . Repeat doses included combination of 400 mcg of misoprostol and 
20 mg ISMN every 4 hours for maximum 4 doses.. 
 
Group 2 - 400 mcg of misoprostol placed intravaginally every 4 hours for 
maximum 4 doses. 
In both the above mentioned groups , T. Mifepristone 600 mg was given 
orally 36-48 hrs prior to termination. 
On Day 1: 
 
 Menstrual history and LMP 
 Past reproductive history 
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 Prior pelvic surgery and known uterine anomalies 
   Medical history and gynaecological examination. 
  Proper pre abortion counselling in the obstetric department. 
   Informed consent 
   Based on Obstetric sonogram to confirm gestational age, placental 
location and   to confirm anomalies 
   Investigations – Haemoglobin and Blood group and Rh typing – If 
negative Anti D is given 
 Screening for common sexually transmitted disease – HIV, VDRL 
 Inj. T.T band prophylactic antibiotics were given to all patients. 
       
Women received mifepristone 600 mg orally and the time of Mifepristone 
administration was noted. Unless abortion occurred following administration of 
mifepristone alone, women were asked to return 36 hours later. 
(Mifepristone enters breast milk and can have endocrine effects on the baby 
and it has half life of 24-48 hours. Hence lactating women are advised to avoid 
breast feeding for 2 days). 
On Day 3 –  
 
Patient admitted in the labour room and treated as in patient. 
 Preparation of parts done. 
 Vitals checked. 
 Per abdomen and per vaginum examination done. 
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  Combination of T.Misoprostol with ISMN or T. Misoprostol alone placed 
in the posterior fornix according to the study group. 
  Reassessment done every 4 th hourly 
  Vitals monitored hourly 
  Analgesics, antipyretics,( Temp >100F) and anti emetics were added if 
required. 
  Side effects like abdominal pain, fever, nausea; vomiting, diarrhoea, 
headache, palpitation, hypotension and tachycardia were noted. 
 
OUTCOMES MEASURED  
 Induction – Abortion Interval 
 Total number of dose 
 Completness of Procedure 
 Failure of abortions 
 Onset of side effects.  
INDUCTION ABORTION INTERVAL: 
Interval measured from first dose of Misoprostol to complete expulsion. 
 
INCOMPLETE ABORTION: 
If the placenta is not delivered within 2 hours, oxytocin 10 units are added 
in 500 ml RL at rate of 20-30 drops/min.  Partial expulsion of products of 
conception who need an additional procedure to complete the evacuation is 
termed as incomplete abortion. 
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FAILURE: 
If the women fails to abort within 48 hrs from first dose of combination of 
misoprostol and ISMN or misoprostol  alone , it is called as failed procedure. 
 
For each woman the outcome of the medical abortion regimen was classified 
into three categories. 
 
 Complete abortion (requiring no further treatment ) 
 Incomplete abortion (foetus expelled but placenta not expelled even after 2 
hours ) 
 Failures 
 
Women with incomplete abortion were further managed by surgical 
intervention. Women with failures were used other methods of medical abortion.  
 
FEVER: Fever was defined as temperature >100.4 F. 
 
DIARRHOEA and VOMITING:  were recorded as side effects if more than two 
episodes occurred. 
 
BLOOD LOSS: Estimated blood loss of more than 250 ml or the need for blood 
transfusion was considered for significant vaginal bleeding. 
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Subjective assessment of the women’s comfort in the two groups was also 
made. The women were discharged 24 hrs after the abortion if there was no 
complication and called for a follow-up visit after 1- 3 weeks. USG was done for 
all patients before discharge. Post abortion contraception counselling was also 
given. 
 
 In presenting the results, continuous variables are presented as means with 
standard deviation and ranges . Difference in continuous variables was analysed 
by student's T-Test for normally distributed data and Mann- Whitney U – test for 
skewed data. The Chi – Squared test or Fischer's exact test was used to compare 
categorical data when appropriate P- value < 0.05 was considered statistically 
significant. 
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OBSERVATION AND RESULTS 
One hundred cases of second trimester abortions were included in this study and 
were assigned to two groups of 50 each randomly. 
 
Group A:  
Number of patients: 50 
Combination of Misoprostol and Isosordibe Mononitrate was used for induction 
of abortion. 
 
Group B: 
Number of patients: 50 
Misoprostol alone was used for induction of abortion. 
The following observations were made and the results interpreted. 
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AGE DISTRIBUTION 
Age of the patients in this study was between 18 and 36 years in both the 
group. The mean age was 24.42 years (Standard Deviation – 4.05) in Group A and 
25.20 years (Standard Deviation – 4.37) in Group B. The maximum number of 
patients seeking mid-trimester abortion is in the age group 21 -25 years. 
AGE GROUP 
(Years) 
GROUP 
TOTAL 
A B 
Less than 20 11 12 23 
21-25 21 14 35 
26 -30 14 19 33 
More than 30 4 5 9 
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PARITY DISTRIBUTION 
Among all the patients studied, in Group A 46% of the patients were 
primigravida and in Group B 38% of the patients were primigravida. In Group A 
54% of the patients were multigravida and in Group B 62 % of the patients were 
multigravida. Most of the patients seeking abortion in both the group were 
multigravida. Among multigravid women most of the patients were second 
gravida. 
PARITY 
GROUP 
Total 
A B 
One 23 19 42 
Two 13 13 26 
Three 8 10 18 
Four 5 6 11 
Five 1 2 3 
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GESTATIONAL AGE 
Among the patients studied the gestational age were between 12 and 20 
weeks. The mean gestational age was 16.24 weeks (Standard Deviation 2.26) and 
16.5 weeks (Standard Deviation 2.42) in Group A and in Group B respectively. 
 
GESTATIONAL AGE 
GROUP 
TOTAL 
A B 
12 – 16 weeks 
16 – 20 weeks 
28 20 48 
22 30 52 
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INDICATION FOR TERMINATION 
The indication for termination in majority of the patients belonging to both 
the group was anomalous baby. Severe PIH and Severe Oligohydramnios were the 
indication in few cases in both the group. 
INDICATIONS 
GROUP 
Total 
A B 
Anomalous Baby 14 16 30 
Contraception Failure 3 3 6 
Intra Uterine Foetal Demise (IUFD) 9 6 15 
Medical Indications 4 7 11 
Preterm Premature Rupture Of Membrane 
(PPROM) 
4 2 6 
Severe Oligohydramnios 2 3 5 
Severe PIH 2 2 4 
Social Causes 12 11 23 
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NUMBER OF DOSES REQUIRED 
In Group A 18% of the patients aborted with one dose whereas in Group B 
14% of the patients aborted with one dose. 56% in Group A and 48% in Group B 
aborted with two doses. In Group A 76% of the patients aborted with two doses 
where as in Group B 62 % of the patients aborted with two doses.  
NUMBER OF DOSES 
GROUP 
TOTAL 
A B 
One 9 7 16 
Two 28 24 52 
Three 11 14 25 
Four 2 5 7 
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DOSE OF MISOPROSTOL REQUIRED 
The mean dose of Misoprostol used in Group A was less when compared 
to the mean dose used in group B, but the dose reduction was not statistically 
significant. 
GROUP 
MEAN DOSE OF MISOPROSTOL USED 
(µg) 
P – Value 
A 848 
0.097 
B 936 
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INDUCTION ABORTION INTERVAL 
 In Group A the mean duration between induction and abortion was 7 hrs 
36 minutes (Standard Deviation 3 hrs 11 min). In Group B the mean duration 
between induction and abortion was 9 hrs 55 minutes (Standard Deviation 4 hrs 
42 min). The P-Value was 0.048 and was statistically significant. 
TIME INTERVAL 
GROUP 
TOTAL 
P – 
VALUE 
A B 
0 – 6 Hrs  18 12 30 
0.048 
6 – 12 Hrs 28 22 50 
12 – 18 Hrs 4 14 18 
18 – 24 Hrs 0 2 2 
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SIDE EFFECTS 
In this study the side effects of the drugs used were found in 38% and 78% 
of the patients in Group A and Group B respectively.  
SIDE EFFECTS GROUP A GROUP B 
Present 19 39 
Absent 31 11 
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COMPARISION OF SIDE EFFECTS 
Side effects like pain abdomen and fever were present in more number of 
patients in Group B when compared to Group A. Major side effects like cervical 
injury and blood loss were absent in both the groups. The side effect profile is 
reduced in Group A when compared to Group B but they are not statistically 
significant. 
SIDE EFFECTS GROUP A GROUP B P – Value 
Fever 2 7 0.318 
Nausea & Vomiting 0 0 0 
Diarrhoea 3 7 0.318 
Shivering 1 1 1 
Abdominal Pain 19 38 0 
Retained Placenta 3 5 0.357 
Cervical Injury 0 0 0 
Blood Loss 0 0 0 
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SIDE EFFECTS SPECIFIC TO ISOSORBIDE MONONITRATE 
 Patients in Group A who were induced with additional drug had the 
following side effects in addition to the above side effects. These side effects 
occurred in only few of the patients.  
SIDE EFFECTS NUMBER OF PATIENTS 
Headache 2 
Hypotension 0 
Tachycardia 0 
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STATUS OF ABORTION 
Among the patients studied 94% in Group A and 80% in Group B had 
complete abortion whereas 6% and 16% of women in Group A and Group B 
respectively had incomplete abortion. There was no failure of abortion in both the 
group. The number of complete abortion were more in Group A when compared 
to Group B but the results were statistically not significant. 
OUTCOME GROUP A GROUP B P  – VALUE 
Complete Abortion 47 40 
0.318 
Incomplete 
Abortion 
3 10 
Failure 0 0 
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PARITY AND INDUCTION ABORTION INTERVAL 
As the gravidity increases the induction abortion interval in both groups 
decreases. This is irrespective of the drug used. 
TIME INTERVAL 
PARITY 
GROUP A GROUP B 
PRIMI MULTI PRIMI MULTI 
0 – 6 Hrs 3 15 5 18 
6 – 12 Hrs 16 12 11 12 
12 – 18 Hrs 4 0 2 0 
18 – 24 Hrs 0 0 1 0 
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PARITY AND MEAN DOSE OF MISOPROSTOL 
As the parity increases the mean dose of misoprostol used reduces 
irrespective of the study group. 
MEAN DOSE OF MISOPROSTOL PARITY 
PRIMI MULTI 
GROUP A 1060 594.5 
GROUP B  1242 686.25 
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 DISCUSSION 
The exact incidence of induced abortion is definitely not known, as 
estimated amount of illegal abortions are not documented reliably. In 2007, it was 
estimated that 42 million abortions occurred each year in the world out of which 
26 million were legal and 20 million were illegal. 
 
The human uterine cervix is a unique organ. It is composed of smooth 
muscle cells (10-15%) and connective tissue (85-90%). During the time of 
pregnancy the cervical stroma mainly consists of extracellular connective tissue, 
type I and III collagen bundles which provide rigidity and competence to the 
cervix. The contents of matrix include water, glycosaminoglycans, and 
proteoglycans as well as dermatan sulfate, hyaluronic acid, and heparin sulfate. 
 
Cervical ripening is an active process, involving a complex cascade of 
degradative enzymes which is  accompanied by degradation and disorganization 
of  collagen framework, an increased water content, and rearrangement of 
extracellular matrix proteins and glycoproteins. It resembles  an inflammatory 
reaction.  
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Prostaglandins are regarded to play a crucial role among the factors that 
regulate cervical ripening. The other factors include: mechanical factors, 
estrogens, cytokines, neuropeptides , and other inflammatory agents 
 
Nitric oxide is a free radical gas, whose  half-life is short - 4 s. It is 
considered as a fundamental mediator of cervical ripening. An ideal cervical-
ripening agent is one that induces cervical remodelling without stimulating 
uterine activity. Nitric oxide donors are one such agent which relaxes the 
myometrium and at the same time induces ripening of cervix. 
 
The current study demonstrates that the combination of ISMN and 
misoprostol is more effective for second trimester termination of pregnancy than 
either ISMN or misoprostol alone and results in a shorter INDUCTION TO 
ABORTION INTERVAL, thus reducing the dosage of drugs used and therefore 
their side effects. 
This is a prospective study done in 100 women with 12 to 20 weeks of pregnancy 
undergoing medical termination. The maternal variables such as marital status, 
age , parity, gestational age were noted. Subsequently the medical abortion 
regimen of 600 mg of Mifepristone and 400 mcg of vaginal misoprostol alone or 
in combination with 40 mg of ISMN was prescribed. The complete abortion rate, 
induction abortion interval, total dose of misoprostol used and side effects of 
misoprostol were noted in group A and B. 
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Several studies have evaluated the use of Iso sorbide mono nitrate for 
termination of pregnancy in second trimester as well as in term. Comparison of 
these studies is difficult because they included women with varying duration and 
different regimens. 
 
AGE: 
The mean age in this study was 24.6 +/- 4 Standard Deviation. The age 
distribution was maximum amongst the 20 to 25 years and least amongst more 
than 30 years. 
 
PARITY: 
 Parity distribution shows the maximal distribution among primi gravida 
women -46% in group A and 38% in group B and the rest were multigravida. In 
this study, all patients aborted without failure  
 In Group A, 37.25% of primigravida and 74% of multigravida aborted 
within 12 hours. Multigravid women took significantly less time to abort (P-value 
-0.044). 
 In Group B, 32% of primigravida and 60 % of multigravida aborted within 
12 hours. As the parity increases the mean induction abortion interval decreases in 
both the groups. 
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GESTATIONAL AGE: 
  
Gestational age distribution was taken as 12 to 16 weeks (56% and 46%) 
and 16 to 20 weeks (44% and 60 %) in group A and group B respectively. The 
minimum gestational age in this study was 12 weeks and the maximum was 20 
weeks with a mean gestational age of 16.05 weeks +/- 2 standard deviation. The 
mean gestational age was 16.24 weeks (Standard Deviation 2.26) and 16.5 weeks 
(Standard Deviation 2.42) in Group A and in Group B respectively. 
 Mean amount of misoprostol used in patients between 12-16 weeks of 
gestation was more or less equal compared with mean amount used in gestation 
between 17- 20 weeks (618 vs 664) in group B and shows no statistical 
significance. 
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INDICATIONS FOR TERMINATION:  
  
The most common indication in the study was Anomalous baby (28 % and 
32 % ) in group A and B respectively. The indications like Severe PIH and Severe 
Oligohydramnios were less. Medical indications included Severe IUGR, 
uncontrolled Diabetes, Maternal medical complications like heart disease, SLE, 
Chronic kidney disease, Chronic liver disease. According to Susanne et al in 2010 
may the most common indication were medical illness, social reasons and 
anomalies. 
 
INDUCTION ABORTION INTERVAL: 
  
In the present study the time taken for complete abortion in group A ranged 
from 2.5 hrs to 15 hrs. In Group A the mean duration between induction and 
abortion was 7 hrs 36 minutes (Standard Deviation 3 hrs 11 min). In Group B the 
mean duration between induction and abortion was 9 hrs 55 minutes (Standard 
Deviation 4 hrs 42 min). The P-Value  was 0.048 and was statistically significant. 
 
 In spite of all the other factors remaining the same, the mean induction 
abortion interval in group A is lesser and is due to the addition of ISMN as an 
additive drug for termination. 
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MEAN DOSE OF MISOPROSTOL USED : 
 
 The mean dose of misoprostol used was lesser in Group A when compared 
to Group B (848 vs. 936) but however it is not statistically significant. The lesser 
mean dose of misoprostol used is attributed to the use of ISMN as an additive 
inducing agent. 
 
MEAN NUMBER OF DOSE USED : 
 
 In Group A 76% of the patients aborted with two doses where as in Group 
B   62 % of the patients aborted with two doses. Though it is not statistically 
significant, the number of doses used for most of the patients in Group A is less 
when compared to Group B, where only 60 % patients aborted with two doses.  
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SUCCESS RATE: 
The success rate of abortion was determined by complete abortion within 
48 hours and in our study it was 94 % in Group A and 80 % in Group B. Also in 
group A almost all the patients aborted within 15 hrs whereas the time was 
prolonged in Group B where ISMN was not added. The complete abortion rate in 
Group A was statistically significant (P value 0.0005). 
 The abortion was considered incomplete if placenta was not expelled 
within 2 hrs or if there was presence of retained products of conception which 
requires an intervention like check curettage. The incomplete abortion rate and 
need for check curettage was higher in group B compared to group A (16 vs. 6 %) 
which is statistically significant. In both the groups there was no failure of 
abortion. 
 There are only few studies reporting regimens for women who do not abort 
within 24 hrs. According to some protocols, if abortion does not occur, 
mifepristone is given followed by repeated vaginal administration of drugs. Any 
patient who fails to abort during the second day will get a third dose of 
mifepristone followed by gemeprost 1 mg every 3 hrs. 
 The concept of genetic variation of the progesterone receptor has been 
postulated in first trimester abortion among women who did not respond to 
mifepristone – PG combination. 
 Still more studies are required to look into the prolonged or failed second 
trimester abortion. 
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SIDE EFFECTS : 
 Side effects like pain abdomen and fever were present in more number of 
patients in Group B when compared to Group A. Apart from pain abdomen and 
fever , the incidence of adverse effects was relatively low in both groups. 
 Pain abdomen was seen in 38 % in Group A and 76 % in Group B. This 
shows that the addition of ISMN has a definite reduction in the side effect. This is 
due to the antagonistic effect of ISMN on myometrial contractility without 
interfering with the abortion process. 
 Side effect specific to ISMN was negligible and reported only in 2 out of 
50 patients. This is in accordance with the study which tells that vaginally ISMN 
has only local absorption and it enters into systemic circulation only after a 
maximum of 100 mg. 
 
SAFETY OF MEDICAL ABORTION : 
 It is important to note that, despite advances in abortion technology , 
procedure related morbidity and mortality increases with gestational age. Vacuum 
aspiration is one of the safest surgical procedures, and the experience with 
medical abortion to date suggests that this method is also safe when provided at 
clinics with adequate back up services .  Antiprogestogen ,Prostaglandins and 
Nitrates have contraindications that have to be respected. As a special precaution, 
the medical method is not recommended for use in women who are older than 35 
years and who smoke more than ten cigarettes a day. 
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NITRATES AS A GOOD CERVICAL RIPENING AGENT : 
 
 Nitrates have an antagonistic effect in the myometrium that is stimulated 
by PGs and relaxed by NO donors, resulting in less frequent episodes of uterine 
hyperactivity. In our study, combination therapy resulted in a slight decrease in 
the incidence of uterine hyperactivity. 
Furthermore, we hypothesized that combining ISMN with misoprostol 
might reduce the side effects associated with either drug alone because the 
smooth-muscle-relaxant properties of ISMN may result in a reduced incidence of 
the side effects attributable to PG-associated gastrointestinal and myometrial 
contractions.  
 
In our study, we found that the addition of ISMN does reduces the 
incidence of abdominal/pelvic pain or the need to opiate analgesia in the first 24 
hours..In contrast, combination therapy reduced significantly the incidence of 
headache. The current study demonstrates that vaginally administered ISMN does 
not affect maternal  hemodynamic .This is in agreement with the findings of 
Nicolle et al in their randomized controlled trial of IMN in the third trimester  
 
A potential concern regarding the use of NO donors is that their uterine-
relaxant effect may promote increased blood loss at the time of delivery. 
However, the current study reveals that the incidence of postpartum haemorrhage 
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was similar in the study groups. This finding is supported by results of previous 
studies. 
 
As no maternal side effects of clinical importance were registered with the 
NO donor ISMN in the current study, such an agent could be given for cervical 
ripening. Maternal enthusiasm for ISMN was clearly evident because maternal 
satisfaction and acceptability were found to be higher in the ISMN and 
misoprostol combination group compared with the misoprostol alone group. 
 
In this study we compare two regimen, Misoprostol with ISMN and 
Misoprostol alone vaginally every 4 hrs following oral mifepristone (600 mg )in 
gestational age between 12 and 20 weeks of pregnancy (second Trimester ) 
 
The abortion rates and the mean induction abortion interval was 
significantly more in Group A when compared to Group B. 
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SUMMARY  
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SUMMARY 
 This comparative study was done in the Department of Obstetrics and 
Gynaecology, Institute of Obstetrics and Gynaecology, Madras Medical College. 
 A total of 100 patients with gestational age 12- 20 weeks pregnancy 
undergoing Medical Termination of Pregnancy were enrolled in this study. 
     OUTCOME GROUPA 
  (Miso and ISMN) 
GROUP B 
( Misoprostol alone) 
InductionAbortion 
Interval 
7 hrs 36 mins 9 hrs 55 mins 
Tot.amt  Misoprostol used 848 mcg 936 mcg 
Complete Abortion rate 94% 80% 
Incomplete Abortion rate 3% 20% 
Side effects present 38% 78% 
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 All patients after appropriate investigations and counselling were given 
oral Mifepristone 600 mg followed 36- 48 hrs later by vaginal misoprostol 
400 mcg with ISMN 40 mg every 4
th
 hrly in one group and vaginal 
misoprostol alone 400 mcg every 4 th hrly in another group. 
 There were no significant changes in considering age, socio economic 
status, marital status, parity and gestational age distribution. 
 The average age was 25 years and the mean parity in this study was 2.8. 
 Most common indication for MTP was anomalous baby and social reasons 
in this study. 
 The mean induction abortion interval was significantly less (7 hrs 36 mins ) 
in Group A, compared with group B(9 hrs 55 min). 
 There was no statistical significant difference in the amount of mean dose 
used in both groups. But however the mean dose decreased in group A 
(848 mcg ) when compared with group B (936  mcg). 
 The mean number of doses was more or less same in both the groups. 
 The complete abortion rate within 48 hrs in Group a A was 94 % which 
shows no statistical significance when compared with Group B complete 
abortion rates (80%). However, it is interpreted that on adding ISMN the 
number of complete abortion rates are higher. 
 There was no failure of abortion in both the groups. 
 The side effects such as pain abdomen and fever were less in Group A(38 
%) when compared to Group B(78%). 
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 Side effects specific to ISMN was very less and reported only in 2 % of 
study groups. There were no significant changes in average Pulse Rate, 
average Systolic BP, and Diastolic BP in the study group before and after 
the administration of intravaginal ISMN. 
 In both the groups, as the parity increases the mean dose of misoprostol 
used and induction abortion rate decreases. 
 None of the patients in study group required extra dose of methergine, 
volume expanders, blood or blood products.  
 The drug ISMN , was also economical and cost effective.  One tablet of 
ISMN (40 mg ) costs around Rs . 4 – Only. Also when ISMN is added 
there is a reduction in hospital stay, manpower, economy spent on patient 
and a sense of well being from the patient also. 
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CONCLUSION 
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CONCLUSION : 
 To conclude Group A (600 mg of Mifepristone on Day 1 followed by 36- 
48 hrs combination of intravaginal Misoprostol and ISMN every 4 th hrly ) shows 
following results : 
 
 100 % abortion rate within 24 hrs 
 The mean induction abortion interval was significantly less 
 There was no failure of abortion. 
 Mean dose of misoprostol used was lesser. 
 Side effects such as pain abdomen and fever were reduced in group A  
 There was no reported evidence of postpartum haemorrhage or increased 
blood loss. 
 
Hence seems to be the effective regimen for second trimester medical abortion 
(12-20 weeks). 
 
The ideal regimen with optimal doses and frequency of administration of 
combined therapy awaits further studies. Vaginally administered ISMN seems to 
be safe and well tolerated and provides a merit in some situations, where uterine 
contractions are unwanted before cervical ripening.      
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ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
 
 Name  :       LMP  : 
 Age  :        EDD  :  
          IP. No.  :       GA    : 
           Parity  : 
         SE   : 
 Indication for Termination  : 
 Chief Complaints  : 
 Menstrual History  : 
 Marital History  : 
 Obstetric History : 
 Past History  : 
 Personal History : 
 Family History  : 
 O/E :  Wt   BP  Pallor 
  Ht  PR  Edema 
 INVESTIGATIONS  : 
  Hb 
  PCV 
  Blood Grouping and Typing 
 USG OBSTERTRICS : 
  IU , GA 
 P/A  :  
 P/S  :  
 P/V ,  Cx Length  :   Mifepristone : 
   OS    :   Time : 
      Dose  : 
 Misoprostol   :  
 Isosorbide Mononitrate  : 
 No. of Doses  : 
  
Time of  Expulsion  : 
 Induction Abortion Interval  : 
 Completeness  : 
 Side Effects  :      ISMN added 
Groups : 
  Vomitting  :      Headache  : 
   
  Fever   :      Palpitation  : 
  Shivering  :      Tachycardia  : 
  Diarrhoea  :      Hypotension  : 
  Abdominal Pain :     Dizziness  : 
 Antibiotics: 
 Any Operative Intervention  : 
 Post Op Follow Up  : 
 
 
 
 
  
 
 
MASTER CHART 
SECOND TRIMESTER TERMINATION WITH INTRAVAGINAL MISOPROSTOL AND ISMN- Group A 1
MISO (µg) ISMN (mg)
1 Shanthi 22 16w2d Primi Anomalous 18 w5 d 3 1200 80 10.5 C
2 Devi 24 14w G2P1L1 Anomalous 14w2d 2 800 60 6 C
3 Vijaya 25 20w G2P1L1 Severe Oligo 20 w 2 800 60 6.2 C
4 Valarmathy 19 13w3d Primi Medical 12w3d 2 800 60 5.4 C
5 Arokiyamal 19 19w Primi PPROM 19w 2 800 60 6 C
6 Leelavathi 24 13w Primi Social 13w 4 1600 100 14 C
7 Uma 26 16w5d G3P2L2 Cont Fail 18w 1 400 40 2.2 C
8 Mary Florence 22 12w4d G2P1L1 Missed AB 13w 2 800 60 5 C
9 Priya 21 14w2d G2A1 Missed AB 14w 1 400 40 3.3 I
10 Khurshed Banu 20 20w Primi Social 19w2d 2 800 60 7 C
11 Anandi 30 17w G2P1L1 Anomalous 18w 1 400 40 3 C
12 Rajeshwari 28 14w G3P2L2 Social 14w2d 1 400 40 2.5 C
13 Noor Jahan 32 18w Primi IUFD 18w 3 1200 80 10 C
14 Amudha 25 20w Primi IUFD 19w6d 3 1200 80 11.3 C
15 Jayanthi 24 17w Primi Anomalous 17w 2 800 60 7 C
16 Revathy 22 184d G2A1 Severe Oligo 18w 2 800 60 7.2 C
17 Bhuvaneshwari 30 20w G4P2L2A1 Social 18w 1 400 40 3 C
18 Hussaina 29 14w2d G2P1L1 Anomalous 14w 2 800 60 8 C
19 Manjula 32 17w G3P2L2 Cont Fail 17w 2 800 60 5.4 C
20 Maya 28 12w6d Primi Medical 13w 3 1200 80 10 C
21 Pusphavalli 22 14w Primi Social 15w2d 2 800 60 7 C
22 Bhavani 25 13w3d G4A3 IUFD 15w 2 800 60 6.3 C
23 Usha 18 14w G5P2L2A2 Social 16w 1 400 40 2.3 C
24 Mary 23 16w3d Primi PPROM 17w 2 800 60 8.5 C
25 Ponni 24 17w Primi Anomalous 17w 3 1200 80 11 C
26 Manimala 19 17w Primi severe PIH 17w2d 2 800 60 9 C
27 Vimala 22 16w2d Primi Anomalous 15w 3 1200 80 12.5 C
28 Susheela 29 15w G2P1L1 IUFD 15w 2 800 60 6 C
29 Kanchana 20 15w4d G2P1L1 Anomalous 16w 2 800 60 8 C
30 Anitha 30 20w G2P1L1 Anomalous 18w 2 800 60 7.3 C
31 Chithra 27 14w G3P2L2 Social 20w 1 400 40 4 C
32 Komala 25 19w5d G3A2 PPROM 20w 2 800 60 8.5 C
33 Megala 28 17w G3P2L2 Cont Fail 16w4d 2 800 60 9 C
34 Maragatham 24 14w5d G4P3L3A1 Social 14w 2 800 60 10.2 C
COMPLETE 
INCOMPLETE
INDICATION USG
DOSES  OF 
ISMN, MISO
TOTAL DOSE
INTERVALS.No. NAME
AGE 
(Yrs)
GA (Weeks) GRAVIDITY
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SECOND TRIMESTER TERMINATION WITH INTRAVAGINAL MISOPROSTOL AND ISMN- Group A 2
MISO (µg) ISMN (mg)
COMPLETE 
INCOMPLETE
INDICATION USG
DOSES  OF 
ISMN, MISO
TOTAL DOSE
INTERVALS.No. NAME
AGE 
(Yrs)
GA (Weeks) GRAVIDITY
35 Subathra 26 15w G3P2L2 Medical 15w 2 800 60 10 C
36 Rani 27 16w2d Primi Social 15w 3 1200 80 13 C
37 Selvi 31 17w Primi Anomalous 17w 3 1200 80 11 C
38 Sumalatha 22 20w Primi Anomalous 20w 4 1600 100 15 I
39 Kathayee 28 12w2d Primi Anomalous 13w 3 1200 80 12 C
40 Rahathi 20 13w G4P2L1A1 Medical 13w3d 2 800 60 7 C
41 Mariam 25 15w G2P1L2 Anomalous 15w 2 800 60 6 C
42 Uagarani 20 16w4d Primi severe PIH 15w5d 2 800 60 7 C
43 Parameshwari 18 17w Primi PPROM 17w 2 800 60 5 C
44 Gangavalli 22 17w G4P3L3 Social 17w 1 400 40 3 C
45 Salma Bee 32 19w2d Primi IUFD 19w 3 1200 80 11 C
46 Rekha 27 12w4d G2A1 IUFD 13w 2 800 60 7 I
47 Thenmozhi 18 15w Primi Social 14w 2 800 60 8 C
48 Kalaivani 24 16w G3P2L2 Social 16w 1 400 40 2.5 C
49 Inbarasi 25 16w 2d G4P3L3 Cont Fail 16w 1 400 40 3.2 C
50 Sankari 26 18w G2A1 Anomalous 18 w5 d 2 800 60 6 C
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SECOND TRIMESTER TERMINATION WITH INTRAVAGINAL MISOPROSTOL AND ISMN- Group A 3
1 Shanthi
2 Devi
3 Vijaya
4 Valarmathy
5 Arokiyamal
6 Leelavathi
7 Uma
8 Mary Florence
9 Priya
10 Khurshed Banu
11 Anandi
12 Rajeshwari
13 Noor Jahan
14 Amudha
15 Jayanthi
16 Revathy
17 Bhuvaneshwari
18 Hussaina
19 Manjula
20 Maya
21 Pusphavalli
22 Bhavani
23 Usha
24 Mary
25 Ponni
26 Manimala
27 Vimala
28 Susheela
29 Kanchana
30 Anitha
31 Chithra
32 Komala
33 Megala
34 Maragatham
S.No. NAME
FEVER SHIVERING
NAUSEA 
VOMITING
DIARRHOEA ADB PAIN HEADACHE
HYPOTENSI
ON
TACHYCAR
DIA
RETAINED 
PLACENTA
- - - - + - - - - No
- - - - + - - - - No
- - - - ++ - - - - No
- - - - + - - - - No
- - - - - - - - - No
+ - - + ++ + - - - No
- - - - - - - - - No
- - - - + - - - - No
- - - - - - - - + Check Curretage
- - - - + - - - - No
- - - - - - - - - No
- - - - + - - - - No
- - - - + - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - + - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - + ++ - - - - No
- - - - + - - - - No
- - - - + - - - + Check Curretage
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
SIDE EFFECTS
INTERVENTION
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SECOND TRIMESTER TERMINATION WITH INTRAVAGINAL MISOPROSTOL AND ISMN- Group A 4
S.No. NAME
35 Subathra
36 Rani
37 Selvi
38 Sumalatha
39 Kathayee
40 Rahathi
41 Mariam
42 Uagarani
43 Parameshwari
44 Gangavalli
45 Salma Bee
46 Rekha
47 Thenmozhi
48 Kalaivani
49 Inbarasi
50 Sankari
FEVER SHIVERING
NAUSEA 
VOMITING
DIARRHOEA ADB PAIN HEADACHE
HYPOTENSI
ON
TACHYCAR
DIA
RETAINED 
PLACENTA
SIDE EFFECTS
INTERVENTION
- - - - + - - - - No
+ - - + + - - - - No
- - - - ++ - - - + Check Curretage
+ + - - ++ + - - - No
- - - - + - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - + - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
- - - - - - - - - No
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TERMINATION WITH INTRAVAGINAL MISOPROSTOL - Group-B 1
S. No. Name AGE (Yrs) GA (Weeks) GRAVIDITY INDICATION USG No. Doses of 
MISO
Dose of MISO INTERVAL
1 Koteshwara 23 17 G2P1L1 Anomaly 17 2 800 9
2 Vijaya Lakshmi 29 14 Primi Anomaly 14 3 1200 12.5
3 Rajini 23 19+2 Primi Severe oligo 19 4 1600 18
4 Kumutha 24 15+3 Primi IUFD 16 2 800 8
5 Reena 20 12+4 Primi Medical 12+6 3 1200 13
6 Bagitha 23 16 Primi Anomaly 16 3 1200 14.3
7 Sharanya 20 14 G4P3L3 Social 14+4 1 400 3
8 Kaviya 24 18+6 G4P2L2A1 Cont failure 18 2 800 7
9 Selvi 24 18+2 G3P2L2 Social 19 1 400 3.4
10 Panjali 33 13+3 G3P2L3 Social 14 2 800 6
11 Piraimathi 24 12+2 G4A3 Missed Ab 13+5 2 800 8
12 Sangeetha 27 18 G5P1L1A4 Medical 17 2 800 9.3
13 Sundari 28 18 Primi Anomaly 17+5 3 1200 12.5
14 Lakshmi 29 16 Primi Anomaly 16 3 1200 14
15 Rajeshwari 27 17+6 Primi Severe PIH 19 4 1600 16
16 Chitra 26 20 G2P1L1 Severe oligo 20 2 800 9
17 Vijaya 19 16+4 G2P1L1 IUFD 16 2 800 10.4
18 Manimegalai 32 17 G2P1L1 IUFD 17 3 1200 14
19 Sudha 20 15 G3P1L1A1 Medical 14+3 2 800 9
20 Hemalatha 24 14 G2A1 Medical 14 2 800 10.2
21 Rani 31 17+2 G2A1 Anomaly 17 3 1200 13
22 Bhuvaneshwari 26 14+3 Primi Social 14 4 1600 20
23 Saranya 23 18 Primi IUFD 19+2 3 1200 15
24 Swathi 19 18 Primi anomaly 18 3 1200 13
25 Nathiya 19 19+5 G3P2L2 Social 19 2 800 7
26 Maheshwari 27 20 G3P1L1A1 Medical 20 2 800 7
TERMINATION WITH INTRAVAGINAL MISOPROSTOL - Group-B 2
S. No. Name AGE (Yrs) GA (Weeks) GRAVIDITY INDICATION USG No. Doses of 
MISO
Dose of MISO INTERVAL
27 Sundari 27 19+1 G4P2L2A1 Cont failure 20 1 400 3
28 Sathya 19 14+6 Primi Anomaly 14 2 800 5.4
29 Shabeena 20 13+2 Primi Anomaly 13 3 1200 11.3
30 Sheela Devi 27 17 Primi Anomaly 16+4 3 1200 11
31 Padma Priya 24 19+6 G3A2 PPROM 18 2 800 6
32 Bhavani 19 18+2 G2P1L1 Anomaly 17+3 2 800 6.3
33 Ezhilarasi 28 15+2 G2P1L1 Anomaly 15 2 800 5
34 Rose Mary 24 17 G2P1L1 Severe PIH 17 2 800 7
35 Gowri 25 20 G4A3 Severe oligo 20 1 400 2
36 Jaya Bharathi 30 19+5 Primi Anomaly 19 3 1200 11
37 Mahalakshmi 25 12+4 Primi Anomaly 12 2 800 9
38 Ambika 27 13+5 Primi Social 14 4 1600 22
39 Dhanalakshmi 28 13 G3P2L2 Social 14 2 800 7.5
40 Priya 36 18 G3P2L2 Social 17+4 1 400 3
41 Bhavani 29 18+2 G3P2L2 Cont failure 20 2 800 9
42 Parameshwari 28 18 G5P3L3A1 Social 18 1 400 2
43 Menaka 29 20 G2P1L2 Social 19+5 3 1200 14
44 Balajothi 28 19+3 G2P1L1 Anomaly 19 2 800 10
45 Kuppu 20 19+6 G2P1L1 PPROM 19 2 800 10.4
46 Pattathurani 23 20 G2A1 IUFD 17 2 800 12
47 Bakiyalakshmi 19 12+4 Primi Medical 12+3 3 1200 15
48 Amalarani 19 15 Primi Anomaly 15 4 1600 18
49 Sumathi 27 12+6 G3P2L2 Social 13 2 800 9
50 Farzana 35 13+4 G4P2L2A1 Medical 13+5 1 400 3
TERMINATION WITH INTRAVAGINAL MISOPROSTOL - Group-B 3
S. No. Name
1 Koteshwara
2 Vijaya Lakshmi
3 Rajini
4 Kumutha
5 Reena
6 Bagitha
7 Sharanya
8 Kaviya
9 Selvi
10 Panjali
11 Piraimathi
12 Sangeetha
13 Sundari
14 Lakshmi
15 Rajeshwari
16 Chitra
17 Vijaya
18 Manimegalai
19 Sudha
20 Hemalatha
21 Rani
22 Bhuvaneshwari
23 Saranya
24 Swathi
25 Nathiya
26 Maheshwari
COMPLETE 
INCOMPLETE
FEVER SHIVERING NAUSEA 
VOMITING
DIARRHOEA ADB PAIN RETAINED 
PLACENTA
INTERVENTION
Complete - - - - + - No
Complete - - - - + - No
Complete + - - - + - No
Complete - - - - - - No
Complete - - - - - - No
Complete + - - - - - No
Complete - - - - - - No
Complete - - - - - - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - - - No
Complete - - - - + - No
Incomplete - -- - - - + Check currette
Complete - - - + - - No
Incomplete + - + + + Check currette
Complete - - - - - - No
Complete - - - - - - No
Complete - - - - + - No
Complete + - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Incomplete + + - + + + Check currette
Complete + - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
TERMINATION WITH INTRAVAGINAL MISOPROSTOL - Group-B 4
S. No. Name
27 Sundari
28 Sathya
29 Shabeena
30 Sheela Devi
31 Padma Priya
32 Bhavani
33 Ezhilarasi
34 Rose Mary
35 Gowri
36 Jaya Bharathi
37 Mahalakshmi
38 Ambika
39 Dhanalakshmi
40 Priya
41 Bhavani
42 Parameshwari
43 Menaka
44 Balajothi
45 Kuppu
46 Pattathurani
47 Bakiyalakshmi
48 Amalarani
49 Sumathi
50 Farzana
COMPLETE 
INCOMPLETE
FEVER SHIVERING NAUSEA 
VOMITING
DIARRHOEA ADB PAIN RETAINED 
PLACENTA
INTERVENTION
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - - - No
Incomplete + - - - + + Check currette
Complete - - - - + - No
Incomplete - - - + + + Check currette
Complete - - - - + - No
Complete - - - - - - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - - + - No
Complete - - - + + - No
Complete - - - - + - No
Complete - - - - + - No
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